Metoprolol succinate vs metoprolol tartrate
Pro Research Analysisby 
Searched over 200M research papers
Pharmacokinetic and Pharmacodynamic Differences: Metoprolol Succinate vs Metoprolol Tartrate
Metoprolol is available in two main salt forms: metoprolol succinate (an extended-release formulation) and metoprolol tartrate (an immediate-release formulation). The key difference lies in their release profiles and dosing schedules. Metoprolol succinate is designed for once-daily dosing, providing a steady release and more consistent plasma concentrations over 24 hours, while metoprolol tartrate is typically taken twice daily and results in more pronounced peaks and troughs in drug levels 810.
Studies show that the extended-release metoprolol succinate maintains a more constant effect on heart rate and blood pressure throughout the day, which can be beneficial for conditions where stable beta-blockade is desired 810. In contrast, metoprolol tartrate’s immediate-release profile may lead to fluctuations in drug effect.
Clinical Efficacy in Heart Failure and Angina
In patients with chronic congestive heart failure, both metoprolol succinate and metoprolol tartrate have similar effects on cardiac and renal function, as measured by parameters like left ventricular diameter and ejection fraction 3456. However, metoprolol succinate is more effective at lowering average heart rate compared to metoprolol tartrate 34. In patients with both chronic heart failure and chronic obstructive pulmonary disease (COPD), metoprolol succinate showed a higher rate of cardiac function improvement, though both forms were similarly safe .
For vasospastic angina, both forms were equally effective in preventing major cardiovascular events such as heart attack, stroke, and death. However, metoprolol succinate was associated with fewer clinically significant angina attacks, while metoprolol tartrate offered greater cost-effectiveness .
Safety and Tolerability
Both metoprolol succinate and tartrate are generally well tolerated, with similar safety profiles in terms of adverse drug reactions 56. Hemodynamic studies in heart failure patients show that both forms produce similar acute and chronic effects on cardiac output, vascular resistance, and stroke volume . The choice between the two may depend more on dosing convenience, patient adherence, and specific clinical scenarios.
Pharmaceutical and Formulation Considerations
Metoprolol succinate’s extended-release formulation is engineered to provide a controlled, steady release of the drug, which can improve patient compliance by reducing dosing frequency and minimizing fluctuations in drug levels 8910. The solid-state properties of the two salts also differ, with metoprolol succinate showing greater stability and more predictable behavior upon temperature changes, which is relevant for manufacturing and storage .
Conclusion
Metoprolol succinate and metoprolol tartrate are both effective beta-blockers with similar safety and efficacy for most cardiovascular conditions. Metoprolol succinate offers the advantage of once-daily dosing, more stable drug levels, and potentially better control of heart rate and angina symptoms, while metoprolol tartrate may be more cost-effective. The choice between them should be guided by clinical needs, patient preference, and economic considerations 13456810.
Sources and full results
Most relevant research papers on this topic